AzTrials
AzTrials

RhinosinusitisNCT07560254

Clinical Outcomes and Patient Satisfaction With Velnez Versus Nasopore in Nasal Surgery

A study testing VELNEZ Nasal Pack and NASOPORE Nasal Pack in people with Rhinosinusitis and Sinusitis, run by Ayu, Inc. at 1 site in Malaysia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This clinical trial evaluated two absorbable nasal packing materials - VELNEZ and NASOPORE - in adult patients (18-70 years) who underwent nasal surgery, including septoplasty, FESS, or turbinoplasty. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Rhinosinusitis, Sinusitis, Chronic Rhino-sinusitis
What is being tested?
VELNEZ Nasal Pack and NASOPORE Nasal Pack
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteMalaysia
Study dates
11 Sep 2024to 20 Jul 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants eligible for the use of a nasal pack (either VELNEZ or Nasopore) in routine clinical practice after a planned nasal surgery.
  • Male and female in the age group of 18 to 70 years. (Both Included)
  • Participants or their LAR who can provide informed consent form in writing.
  • Participants who allow their study data to be collected at pre-defined follow-up period.

Who cannot join

  • Participants who are unable to be treated with VELNEZ, or Nasopore nasal pack in routine clinical practice after a planned surgery.
  • Participant's/ legal guardian (LAR) who cannot provide informed Consent written.
  • Participant unwilling or unable to comply with the postoperative visits necessary for data collection.
  • Participant with an active infection at the surgery site.
  • Participant with a history of asthma.
  • Pregnant or lactating Females
Show all 11Show fewer
  • Participant who are on aspirin or anti-platelet drugs therapy.
  • Participant positive for HIV, HCV, VDRL, HBs Ag.
  • Participant who is allergic (Hypersensitive) to any of the ingredients of the nasal packs.
  • Participant with bleeding disorders.
  • Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for inclusion (e.g., a chronic, relapsing or hereditary disease that may interfere with the outcome of the study).

Trial locations and contacts

1 site in 1 country.

Malaysia1 site
  • Hospital Al-Sultan Abdullah, Universiti Teknologi MARA, Jalan Hospital, UiTM Sungai Buloh Campus

    Sungai Buloh, Selangor, 47000

Other trials in Malaysia

About this study

Official title: A Prospective, Open-Labelled, Single-Center, Two-Arm, Randomized Clinical Study to Compare Patient Satisfaction and Clinical Outcome Associated With Two Nasal Packs (VELNEZ Vs NASOPORE) in Nasal Surgery.

This clinical trial evaluated two absorbable nasal packing materials - VELNEZ and NASOPORE - in adult patients (18-70 years) who underwent nasal surgery, including septoplasty, FESS, or turbinoplasty.

The study addressed two core questions: whether VELNEZ offered superior haemorrhage control and faster biodegradation, and whether it reduced postoperative pain, fibrosis, adhesion, and discomfort compared to NASOPORE.

Participants were randomised to receive either packing material following surgery. They were monitored on the day of surgery for haemostasis and device performance, then followed up with clinical and endoscopic assessments - including pain scoring and adverse event tracking - through Day 90.

Read the detailed description

This study was a prospective, randomised, open-label, single-centre, two-arm parallel clinical investigation conducted in a post-market setting. It was designed to evaluate and compare the clinical performance of two biodegradable nasal packing materials - VELNEZ and NASOPORE - following routine nasal surgical procedures under real-world conditions.

Rationale and background Nasal packing is routinely employed after septoplasty, FESS, and turbinoplasty to achieve haemostasis, support mucosal healing, and prevent postoperative complications including adhesions and septal haematoma. Conventional non-absorbable packing materials, while effective for haemostasis, are associated with significant patient discomfort, pain at removal, mucosal trauma, and risk of delayed healing. Biodegradable alternatives were developed to address these limitations by obviating the need for mechanical removal and providing a more favourable postoperative environment.

Investigational devices VELNEZ is a biodegradable composite nasal packing material comprising gelatin, chitosan, polyvinyl alcohol, and psyllium husk. Following placement, it was designed to fragment and gradually dissolve within the nasal cavity over several days. Its composition was intended to deliver effective haemostasis, physically separate mucosal surfaces to reduce adhesion formation, and support tissue regeneration - all without requiring removal, thereby minimising procedure-related trauma and improving patient tolerability.

NASOPORE is a biosynthetic, biodegradable polyurethane foam with established clinical use. Its hydrophilic properties allowed it to absorb fluids and conform to the contours of the nasal cavity, providing mechanical support and haemostatic function. Degradation occurred through fragmentation over time, though the rate and completeness of dissolution varied across patients.

Study design and randomisation Participants were assigned in a 1:1 ratio to receive either VELNEZ or NASOPORE as postoperative nasal packing immediately following surgery. Randomisation was performed to minimise selection bias. Given the physical and visual differences between the two materials, blinding of investigators and participants was not feasible; the study was therefore conducted in an open-label manner.

Clinical assessments and follow-up

Assessments were conducted perioperatively and at scheduled postoperative visits through the final follow-up at Day 90. The evaluation framework covered the following domains:

Device performance: Ease of placement, conformability to nasal anatomy, and haemostatic effectiveness were assessed perioperatively. Degradation profile was monitored clinically at each follow-up; irrigation or manual intervention was performed where incomplete dissolution was observed.

Mucosal and structural healing: Endoscopic examination of the surgical site was performed at applicable visits to evaluate mucosal condition, presence of oedema, secretions, fibrosis, scar formation, and adhesion development. Any pressure-related discomfort or structural changes were documented.

Patient-reported outcomes: Symptom burden and quality of life were assessed using the Sino-Nasal Outcome Test (SNOT-22), a validated instrument for sinonasal conditions. Pain and tolerability were evaluated using standardised pain assessment scales at defined time points.

Safety monitoring: Adverse events and serious adverse events were recorded throughout the study. Device-related complications - including infection, hypersensitivity reactions, and signs of delayed healing - were specifically monitored. Vital signs, physical examinations, and laboratory evaluations were conducted per routine clinical practice.

Statistical approach Continuous variables were summarised using descriptive statistics and compared between groups using parametric or non-parametric tests, selected based on data distribution. Categorical variables were analysed using Chi-square or Fisher's exact test, as appropriate. All analyses were conducted at a two-sided significance level.

Ethical and regulatory conduct The study was conducted in accordance with Good Clinical Practice (GCP) and the ethical principles of the Declaration of Helsinki. Institutional Ethics Committee approval was obtained prior to initiation. All participants provided written informed consent before enrolment.

Being tested
VELNEZ Nasal Pack, NASOPORE Nasal Pack
Keywords
VELNEZ, NASOPORE, Nasal Packing, Biodegradable Nasal Pack, Functional Endoscopic Sinus Surgery, Septoplasty, Rhino Sinusitis
Medical subject headings
Rhinosinusitis, Sinusitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VELNEZ Nasal PackDevice

    Also called VELNEZ

    VELNEZ is a biodegradable composite nasal packing material composed of gelatin, chitosan, polyvinyl alcohol, and psyllium husk. It is designed to fragment and degrade within the nasal cavity after app

  • NASOPORE Nasal PackDevice

    Also called NASOPORE

    NASOPORE is a biosynthetic biodegradable polyurethane foam nasal packing material. It absorbs fluids, conforms to the nasal cavity, and gradually fragments over time. The device is used for postoperative bleeding control, support of nasal structures, and facilitation of healing following nasal surgery.

Study groups in NCT07560254
Study groupRoleWhat they receive
Arm 1: VELNEZ Nasal PackExperimentalParticipants undergoing planned nasal surgery received the VELNEZ biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice. The device was intended to provide haemostasis, support mucosal healing, and reduce postoperative complication
Receives: Device: VELNEZ Nasal Pack
Arm 2: NASOPORE Nasal PackActive comparatorParticipants undergoing planned nasal surgery received the NASOPORE biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice. The device was intended to provide haemostasis and structural support within the nasal cavity during the healing process.
Receives: Device: NASOPORE Nasal Pack

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Success of Nasal Pack

    Proportion of participants achieved successful clinical outcome defined as complete degradation of the nasal pack within 7 days without device-related adverse events, along with acceptable levels of fibrosis and scar formation, absence of moderate to severe postoperative pain, and no significant breathing discomfort due to pressure effect

    Measured: Up to Day 90 post-surgery

Secondary outcomes (5)
  1. Postoperative Pain Assessment using Visual Analogue Scale (VAS)

    Patient-reported pain levels will be assessed using the Visual Analogue Scale (VAS), a 10 cm horizontal line anchored by "no pain" (score = 0) and "worst imaginable pain" (score = 10). The total score ranges from 0 to 10. Higher scores indicate greater pain intensity and worse outcome (lower tolerability of the nasal pack).

    Measured: From Day 0 to Day 14 post-nasal surgery

  2. Time to Haemorrhage Control

    Time (in minutes) from application of the nasal pack at completion of surgery to achievement of complete haemostasis, as assessed by the operating surgeon

    Measured: Day 0 (Intraoperative)

  3. Adhesion Formation (Endoscopic Assessment)

    Incidence and severity of nasal adhesions assessed using endoscopic examination during follow-up visits.

    Measured: Up to Day 90 post-surgery on post surgery follow up visits

  4. Endoscopic Healing Assessment

    Assessment of nasal mucosal healing based on endoscopic findings including mucosal oedema, nasal secretions, and presence of polyps during follow-up visits

    Measured: From Day 7 to Day 90 post-surgery

  5. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number and proportion of participants experiencing adverse events, serious adverse events, or device-related complications during the study period.

    Measured: From Day 0 to Day 90 post-surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2026
  2. Study start11 Sep 2024
  3. Primary completion11 Apr 2025
  4. Study completion20 Jul 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study followed a parallel assignment model in which participants were randomised in a 1:1 ratio to receive either VELNEZ or NASOPORE as postoperative nasal packing. Each participant was assigned to a single treatment arm and remained in that arm throughout the study; no crossover occurred. The allocation sequence was determined using a predefined randomisation schedule to minimise selection bias and ensure balanced distribution across treatment groups. Given the physical differences between the two devices, blinding was not feasible; the study was therefore conducted in an open-label manner, with both investigators and participants aware of the assigned intervention. Both devices were applied intraoperatively or immediately postoperatively as part of routine surgical care. All participants received standard perioperative and postoperative management, with clinical assessments conducted at predefined follow-up time points to evaluate device performance, outcomes, and safety.
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07560254
Sponsor's protocol ID
DMPL/CIP-002-2024/CT/VN
Status last verified
Apr 2026
First submitted
24 Apr 2026
Last updated
6 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data (IPD) will not be shared due to confidentiality considerations. Aggregated study results will be made available through publications.

Questions about this trial

What is this clinical trial studying?

A study testing VELNEZ Nasal Pack and NASOPORE Nasal Pack in people with Rhinosinusitis and Sinusitis, run by Ayu, Inc. at 1 site in Malaysia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Success of Nasal Pack (time frame: Up to Day 90 post-surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in